Translate Bio

Translate Bio is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction and to prevent infectious diseases by inducing protective immunity. Translate Bio is primarily focused on applying its technology to treat pulmonary diseases, with its lead pulmonary candidate being evaluated as an inhaled treatment for cystic fibrosis in a Phase 1/2 clinical trial. Translate Bio is also collaborating with Sanofi Pasteur to develop mRNA vaccines for infectious diseases.